Price
$0.685
Decreased by -2.14%
Dollar Volume
124.92 K
ADR%
8.87
Earnings Report Date (estimate)
Feb 13, 23 (-0.11)
Market Cap.
30.56 M
Shares Float
35.62 M
Shares Outstanding
44.61 M
Beta
1.10
Price / Earnings
-1.50
BPR
34.45
20D Range
0.59 0.84
50D Range
0.34 0.84
200D Range
0.34 1.23
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Feb 14, 22 -0.11
Increased by +67.65%
-0.08
Decreased by -37.50%
Nov 16, 20 -0.01
Increased by +93.33%
-0.07
Increased by +85.71%
Aug 13, 20 -0.07
Increased by +68.18%
-0.08
Increased by +12.50%
Jun 29, 20 0.24
Increased by +442.86%
-0.12
Increased by +300.00%
Nov 13, 19 -0.34
Increased by +45.16%
-0.11
Decreased by -209.09%
Aug 14, 19 -0.15
Increased by +34.78%
-0.17
Increased by +11.76%
Jun 26, 19 -0.22
Decreased by -173.33%
-0.10
Decreased by -120.00%
Feb 14, 19 -0.07
Increased by +76.67%
-0.10
Increased by +30.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-4.93 M
Decreased by -602.45%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-4.52 M
Decreased by -45.09%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-3.90 M
Increased by +30.85%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-3.78 M
Decreased by -17.33%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
981.00 K
Increased by +115.96%
Increased by +N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-3.12 M
Increased by +33.18%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 115.00 K
Increased by +N/A%
-5.65 M
Decreased by -132.78%
Decreased by -4.91 K%
Decreased by N/A%
Dec 31, 20 81.00 K
Increased by +N/A%
-3.22 M
Increased by +73.26%
Decreased by -3.98 K%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.